CLOVER BIO-B (02197) Initiates Phase 2 Clinical Trial for RSV-hMPV-PIV3 Respiratory Combination Vaccine Candidate

Stock News01-12

CLOVER BIO-B (02197) announced that its self-developed Pre-F trimer subunit recombinant protein respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed based on the company's proprietary Trimer-Tag vaccine platform, have completed the enrollment of the first cohort of subjects in Australia, officially commencing a Phase 2 clinical trial. The ongoing Phase 2 clinical trial for Clover's respiratory combination vaccine candidate in Australia is a randomized, observer-blinded, multi-center study planning to enroll up to 420 elderly subjects aged 60-85 years. Participants will be randomly administered either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3), or a placebo. The study will evaluate the vaccine's safety, reactogenicity, and immunogenicity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155208584?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 12:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155208584","market":"other","top_or_hot":-1,"title":"CLOVER BIO-B (02197) Initiates Phase 2 Clinical Trial for RSV-hMPV-PIV3 Respiratory Combination Vaccine Candidate","media":"Stock News","content":"<p>CLOVER BIO-B (02197) announced that its self-developed Pre-F trimer subunit recombinant protein respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed based on the company's proprietary Trimer-Tag vaccine platform, have completed the enrollment of the first cohort of subjects in Australia, officially commencing a Phase 2 clinical trial. The ongoing Phase 2 clinical trial for Clover's respiratory combination vaccine candidate in Australia is a randomized, observer-blinded, multi-center study planning to enroll up to 420 elderly subjects aged 60-85 years. Participants will be randomly administered either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3), or a placebo. The study will evaluate the vaccine's safety, reactogenicity, and immunogenicity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOVER BIO-B (02197) Initiates Phase 2 Clinical Trial for RSV-hMPV-PIV3 Respiratory Combination Vaccine Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOVER BIO-B (02197) Initiates Phase 2 Clinical Trial for RSV-hMPV-PIV3 Respiratory Combination Vaccine Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 12:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOVER BIO-B (02197) announced that its self-developed Pre-F trimer subunit recombinant protein respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed based on the company's proprietary Trimer-Tag vaccine platform, have completed the enrollment of the first cohort of subjects in Australia, officially commencing a Phase 2 clinical trial. The ongoing Phase 2 clinical trial for Clover's respiratory combination vaccine candidate in Australia is a randomized, observer-blinded, multi-center study planning to enroll up to 420 elderly subjects aged 60-85 years. Participants will be randomly administered either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3), or a placebo. The study will evaluate the vaccine's safety, reactogenicity, and immunogenicity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1155208584","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155208584","pubTimestamp":1768192708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOVER BIO-B (02197) announced that its self-developed Pre-F trimer subunit recombinant protein respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02197":"三叶草生物-B"},"translate_title":"三叶草生物-B(02197)启动RSV-hMPV-PIV3呼吸道联合疫苗候选物2期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"CLOVER BIO-B (02197) announced that its self-developed Pre-F trimer subunit recombinant protein respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed based on the company's proprietary Trimer-Tag vaccine platform, have completed the enrollment of the first cohort of subjects in Australia, officially commencing a Phase 2 clinical trial. The ongoing Phase 2 clinical trial for Clover's respiratory combination vaccine candidate in Australia is a randomized, observer-blinded, multi-center study planning to enroll up to 420 elderly subjects aged 60-85 years. Participants will be randomly administered either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3), or a placebo. The study will evaluate the vaccine's safety, reactogenicity, and immunogenicity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155208584","isCrawlerRequest":true}